Our Science – Ho Website
Mitchell Ho, Ph.D.
Selected Publications |
| 1)
Feng M, Gao W, Wang R, Chen W, Man YG, Figg WD, Wang XW, Dimitrov DS, Ho M. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A. 110: E1083-91, 2013. [Journal] |
| 2)
Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, Croix BS, Qian M, Dimitrov DS, Ho M. A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface. Mol. Cancer Ther. [Epub ahead of print], 2013. [Journal] |
| 3)
Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol. Res. 43: 147-54, 2013. [Journal] |
| 4)
Tang Z, Qian M, Ho M. The role of mesothelin in tumor progression and targeted therapy. Anticancer Agents Med Chem. 13: 276-80, 2013. [Journal] |
| 5)
Ho M, Royston I, Beck A. 2 (nd) PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA. MAbs. 4: 562-70, 2012. [Journal] |
| 6)
Phung Y, Gao W, Man YG, Nagata S, Ho M. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening. MAbs. 4: 592-9, 2012. [Journal] |
| 7)
Kim H, Phung Y, Ho M. Changes in Global Gene Expression Associated with 3D Structure of Tumors: An Ex Vivo Matrix-Free Mesothelioma Spheroid Model. PLoS ONE. 7: e39556, 2012. [Journal] |
| 8)
Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur. J. Cancer. 47: 333-8, 2011. [Journal] |
| 9)
Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int. J. Cancer. 128: 2020-30, 2011. [Journal] |
| 10)
Feng M, Kim H, Phung Y, Ho M. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int. J. Cancer. 128: 2246-7, 2011. [Journal] |
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/11/2013.
